Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer

New England Journal of Medicine

Volumn 360, Issue 6, 2009, Pages 563-572

  Tol, Jolien ^a   Koopman, Miriam ^a   Cats, Annemieke ^b   Rodenburg, Cees J ^c   Creemers, Geert J M ^d   Schrama, Jolanda G ^e   Erdkamp, Frans L G ^f   Vos, Allert H ^g   Van Groeningen, Cees J ^h   Sinnige, Harm A M ⁱ   Richel, Dirk J ^j   Voest, Emile E ^k   Dijkstra, Jeroen R ^a   Vink Börger, Marianne E ^a   Antonini, Ninja F ^b   Mol, Linda ^l   Van Krieken, Johan H J M ^a   Dalesio, Otilia ^b   Punt, Cornelis J A ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c MEANDER MEDICAL CENTER   (Netherlands)

^d CATHARINA HOSPITAL   (Netherlands)

^e Infection and Immunology   (Netherlands)

^f Sittard Geleen Heerlen   (Netherlands)

^g BERNHOVEN HOSPITAL   (Netherlands)

^h VU UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁱ JEROEN BOSCH HOSPITAL   (Netherlands)

^j ACADEMIC MEDICAL CENTER   (Netherlands)

^k UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^l Integraal Kankercentrum Oost   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; OXALIPLATIN; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; KRAS PROTEIN, HUMAN; MONOCLONAL ANTIBODY; ONCOPROTEIN; PLATINUM COMPLEX; RAS PROTEIN; VASCULOTROPIN A;

ADD ON THERAPY; ADULT; AGED; ARTERIAL THROMBOEMBOLISM; ARTICLE; BLEEDING; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DISEASE FREE SURVIVAL; DRUG DOSE INCREASE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GENE MUTATION; HUMAN; HYPERSENSITIVITY REACTION; HYPERTENSION; INFECTION; KRAS GENE; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY; SKIN MANIFESTATION; SURVIVAL TIME; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR GENE; VENOUS THROMBOEMBOLISM; VOMITING; COLORECTAL TUMOR; DRUG ANTAGONISM; GENETICS; IMMUNOLOGY; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MUTATION; PATHOLOGY; TREATMENT FAILURE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS; PROTO-ONCOGENE PROTEINS; QUALITY OF LIFE; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT FAILURE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 59749091477     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa0808268     Document Type: Article

References (26)

1. Koopman M, Antonini NF, Douma J, et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet 2007;370: 135-42.
2. Seymour MT, Maughan TS, Ledermann JA, et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet 2007;370: 143-52. [Erratum, Lancet 2007;370:566.]
3. Diaz-Rubio E, Tabernero J, Gómez-España A, et al. Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as firstline therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial. J Clin Oncol 2007;25:4224-30.
4. Porschen R, Arkenau HT, Kubicka S, et al. Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. J Clin Oncol 2007;25:4217-23.
5. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.
6. Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E, Sarkar S. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 2005;23:3706-12.
7. Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008;26:2013-9. [Erratum, J Clin Oncol 2008;26:3110.]
8. Jonker DJ, O'Callaghan CJ, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007;357:2040-8.
9. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-45.
10. Tol J, Koopman M, Rodenburg CJ, et al. A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colo-rectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG): an interim analysis of toxicity. Ann Oncol 2008;19:734-8.
11. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-16.
12. Ciardiello F, Bianco R, Damiano V, et al. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin Cancer Res 2000;6:3739-47.
13. Jung YD, Mansfield PF, Akagi M, et al. Effects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model. Eur J Cancer 2002;38:1133-40.
14. Shaheen RM, Ahmad SA, Liu W, et al. Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors. Br J Cancer 2001;85:584-9.
15. Tonra JR, Deevi DS, Corcoran E, et al. Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy. Clin Cancer Res 2006;12:2197-207.
16. Hecht JR, Mitchell E, Chidiac T, et al. An updated analysis of the safety and efficacy of oxaliplatin (Ox)/bevacizumab (bev) +/- panitumumab (pmab) for first-line treatment (tx) of metastatic colorectal cancer (mCRC) from a randomized, controlled trial (PACCE). In: Program and abstracts of the 2008 Gastrointestinal Cancers Symposium, Orlando, FL, January 25-27, 2008. abstract.
17. Hecht JR, Mitchell E, Chidiac T, et al. Interim results from PACCE: Irinotecan (Iri)/ bevacizumab (bev) +/- panitumumab (pmab) as first-line treatment (tx) for metastatic colorectal cancer (mCRC). In: Proceedings and abstracts of the 2008 Gastrointestinal Cancers Symposium, Orlando, FL, January 25-27, 2008. abstract.
18. Saltz LB, Lenz HJ, Kindler HL, et al. Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecanrefractory colorectal cancer: the BOND-2 study. J Clin Oncol 2007;25:4557-61.
19. Bokemeyer C, Staroslawska E, Makhson A, et al. Cetuximab plus 5-FU/LV/oxaliplatin (FOLFOX-4) in the firstline treatment of metastatic colorectal cancer (mCRC): a large-scale phase II study, OPUS. Presented at the European Cancer Conference 2007, Barcelona, September 23-27, 2007. abstract.
20. Van Cutsem E, Nowacki M, Lang I, et al. Randomized phase III study of irinotecan and 5FU/LV with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): the CRYSTAL trial. Proc Am Soc Clin Oncol 2007;25:164S. abstract.
21. Scartozzi M, Galizia E, Chiorrini S, et al. Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann Oncol 2008 Oct 7 (Epub ahead of print).
22. De Roock W, Piessevaux H, De Schutter J, et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 2008;19:508-15.
23. Liévre A, Bachet JB, Boige V, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008;26:374-9.
24. Karpatis CS, Khambata-Ford S, Jonker DJ, et al. K-RAS mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359:1757-65.
25. Bokemeyer C, Bondarenko I, Hartmann JT, et al. KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: the OPUS experience. J Clin Oncol 2008;26: Suppl:178s. abstract.
26. Van Cutsem E, Lang I, D'haens G, et al. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: the CRYSTAL experience. J Clin Oncol 2008; 26:Suppl:5s. abstract.